Systemic Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Systemic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 381 trials

Recruiting
Not Applicable

Dose Response of Exercise for Arthritis Management

ArthritisGoutRheumatoid Arthritis (RA)+3 more
University of South Carolina285 enrolled1 locationNCT06880653
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
UCB Biopharma SRL450 enrolled219 locationsNCT06617325
Recruiting

Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.

Lupus Erythematosus, Systemic
AstraZeneca218 enrolled19 locationsNCT07330245
Recruiting
Phase 2

To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE)
Hangzhou Sumgen Biotech Co., Ltd.120 enrolled1 locationNCT07447986
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

Idiopathic Inflammatory MyopathiesSystemic Sclerosis
Nkarta, Inc.144 enrolled15 locationsNCT06733935
Recruiting

Patient-Centered Assessment of Symptoms and Outcomes

Myalgic Encephalomyelitis/Chronic Fatigue SyndromeCancerFatigue+5 more
National Center for Complementary and Integrative Health (NCCIH)692 enrolled1 locationNCT03952624
Recruiting
Phase 1

Avapritinib With Decitabine in Patients With SM-AHN

Systemic Mastocytosis With an Associated Hematologic Neoplasm
H. Lee Moffitt Cancer Center and Research Institute34 enrolled7 locationsNCT06327685
Recruiting
Phase 1

A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)

Rheumatoid ArthritisSystemic Lupus Erythematosus
Merck Sharp & Dohme LLC21 enrolled4 locationsNCT07363590
Recruiting
Early Phase 1

Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07507201
Recruiting

Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions

ArthritisStill's Disease, Adult-OnsetSystemic Inflammation+1 more
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)2,000 enrolled1 locationNCT03510442
Recruiting

Study of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)2,000 enrolled1 locationNCT00001372
Recruiting
Phase 3

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic
Viatris Innovation GmbH420 enrolled216 locationsNCT05648500
Recruiting
Phase 1

A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)

Rheumatoid ArthritisHealthy VolunteersSystemic Lupus Erythematosus
Capstan Therapeutics64 enrolled1 locationNCT06917742
Recruiting
Phase 4

A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

Systemic Lupus Erythematosus (SLE)Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
Bristol-Myers Squibb35 enrolled4 locationsNCT06875960
Recruiting
Phase 2

A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis

Systemic Sclerosis
Galderma R&D162 enrolled3 locationsNCT07047690
Recruiting
Phase 3

A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases

Interstitial Lung DiseasesSystemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Boehringer Ingelheim400 enrolled158 locationsNCT06806592
Recruiting
Phase 1

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 3

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Lymphoma, T-CellPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T-cell Lymphoma+4 more
Corvus Pharmaceuticals, Inc.150 enrolled27 locationsNCT06561048
Recruiting
Phase 2

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

Systemic Sclerosis
Hospital for Special Surgery, New York30 enrolled1 locationNCT03844061
Recruiting
Early Phase 1

TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis

Systemic Scleroderma
City of Hope Medical Center15 enrolled1 locationNCT04380831